1 Min Read
Aug 31 (Reuters) - Oncbiomune Pharmaceuticals Inc
* Oncbiomune awaits approval from regulatory committee to commence phase 2 trial of proscavax as front line prostate cancer treatment Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.